Category: News
-
ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment
ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the first patient has been dosed in its Phase 2 clinical trial of ONL1204 Ophthalmic Solution in patients with macula-off rhegmatogenous retinal detachment (RRD).
-
ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Presentation will review the results of ONL’s Phase 1 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal DetachmentPreclinical data in models of inherited retinal degeneration and age-related macular degeneration…
-
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial
ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial Funding supports Phase 2 clinical study of ONL1204 Ophthalmic Solution to evaluate safety and efficacy in patients with macula-off rhegmatogenous retinal detachment ANN ARBOR, MI – March 8, 2023 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company…
-
ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research
ONL Therapeutics to Present at the XXVth Biennial Meeting of the International Society for Eye Research Oral presentation will review the scientific rationale for Fas receptor inhibition, a unique mechanism-of-action, in the treatment of patients with progressing open-angle glaucoma (OAG) ANN ARBOR, MI – February 13, 2023 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel…
-
ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference
ONL Therapeutics to Present at 2023 BIO CEO & Investor Conference ANN ARBOR, MI – February 2, 2023 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, announced today that David Esposito, chief executive officer, will present a corporate update at the BIO CEO & Investor Conference…
-
ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution
ONL Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for ONL1204 Ophthalmic Solution First-in-class small molecule Fas inhibitor with unique mechanism of action is designed to provide neuroprotection for retinal cells ANN ARBOR, MI – February 1, 2023 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with…
-
ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research
ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research Oral presentations will focus on latest findings for ONL1204 Ophthalmic Solution in patients with geographic atrophy associated with dry age-related macular degeneration ANN ARBOR, MI – January…
-
AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Study
AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Study • ONL closed the second tranche of a $46.9 million Series B financing round earlier this year• ONL now preparing IND filing for a Phase 2 study of ONL1204 Ophthalmic Solution• AmbioPharm providing manufacturing support for ONL1204 NORTH AUGUSTA, SC &…
-
ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer
ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer ANN ARBOR, MI – February 9, 2022 ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Sushanta Mallick, PhD, MBA, to the newly created position of Chief Development Officer. As CDO, Dr.…